|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:dateCreated |
1994-3-17
|
|
pubmed:abstractText |
Based upon their individual clinical activity and combined effects in animal models or in vitro, we wished to evaluate a regimen of cisplatin, interferon-alpha, and IL-2 in patients with metastatic melanoma.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1059-2725
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
Doc No 9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
[3841 words; 32 paragraphs]
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:1343617-Adult,
pubmed-meshheading:1343617-Aged,
pubmed-meshheading:1343617-Cisplatin,
pubmed-meshheading:1343617-Combined Modality Therapy,
pubmed-meshheading:1343617-Female,
pubmed-meshheading:1343617-Humans,
pubmed-meshheading:1343617-Interferon-alpha,
pubmed-meshheading:1343617-Interleukin-2,
pubmed-meshheading:1343617-Male,
pubmed-meshheading:1343617-Melanoma,
pubmed-meshheading:1343617-Middle Aged,
pubmed-meshheading:1343617-Nausea,
pubmed-meshheading:1343617-Recombinant Proteins,
pubmed-meshheading:1343617-Vomiting
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with metastatic melanoma. A phase II Study.
|
|
pubmed:affiliation |
Clinical Research Branch, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland 21701.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
